| Mary Kay Snedden, | |
|
2402 Northwest 195th Place, Shoreline, WA 98177-2932 | |
| (206) 364-3777 | |
| (206) 364-3999 |
| Full Name | Mary Kay Snedden |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2402 Northwest 195th Place, Shoreline, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386851343 | NPI | - | NPPES |
| 7300965 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL00003297 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Kay Snedden, 2402 Northwest 195th Place, Shoreline, WA 98177-2932 Ph: (206) 364-3777 | Mary Kay Snedden, 2402 Northwest 195th Place, Shoreline, WA 98177-2932 Ph: (206) 364-3777 |
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.
Published in the journal Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]), the study shows that it is the absence of quality connections with people and not the lack of contact that predicts the onset of type 2 diabetes, suggesting that helping people form and experience positive relationships could be a useful tool in prevention strategies for type 2 diabetes.
In a breakthrough that could lead to new treatments for patients with malignant melanoma, researchers from Mount Sinai School of Medicine have discovered that a particular protein suppresses the progression of melanoma through regulation of an oncogene, or gene responsible for cancer growth. The study is published in the December 23 issue of Nature.
› Verified 7 days ago
Kristi Jill Marion, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Mrs. Jisun Park, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 816 Ne 190th St, Shoreline, WA 98155 Phone: 206-364-3777 | |
April Grace Lagutang Lloyd, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2818 Ne 145th St, Shoreline, WA 98155 Phone: 206-418-2900 | |
Lisa J Vanhorne, MSCCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 340 Nw 177th St, Shoreline, WA 98177 Phone: 206-546-5012 | |
Sarah Burt, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Francesca Blasen, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2402 Nw 195th Pl, Shoreline, WA 98177 Phone: 206-364-3777 Fax: 206-364-3999 | |
Andrea Ryan, MACCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16357 Aurora Ave N, Shoreline, WA 98133 Phone: 206-542-3103 Fax: 206-542-4813 |